In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva buys Novopharm's generic business for $258mm

Executive Summary

Teva (Israeli generics company) is entering the Canadian market through the purchase of the generics business of Novopharm from Dan Family Holdings for $257.88mm in Teva stock. The acquisition does not include Novopharm's OTC business--which will be sold--or Novopharm Biotech, which is publicly traded.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies